Evidence-Based Benefits
- Senolytic activity — quercetin combined with dasatinib is the most studied senolytic cocktail in clinical research; a 2019 pilot trial (Justice et al.) demonstrated clearance of senescent cells in patients with diabetic kidney disease, reducing inflammatory markers
- Immune modulation — quercetin stabilizes mast cells and reduces histamine release, which may help manage allergic responses; a 2016 review found quercetin inhibited pro-inflammatory cytokines IL-6, IL-8, and TNF-alpha
- Anti-inflammatory — quercetin inhibits NF-kB and COX-2 pathways, two central drivers of chronic inflammation, with effects demonstrated in both cell culture and human supplementation trials
- Cardiovascular support — a meta-analysis of 7 RCTs (Serban et al., 2016) found quercetin supplementation significantly reduced systolic blood pressure by 3.04 mmHg in hypertensive individuals
- Enhanced bioavailability via phytosome — quercetin phytosome (Quercefit) achieves up to 20x greater plasma levels than standard quercetin dihydrate, meaning lower doses produce stronger effects